Androgen deprivation therapy (ADT) directly targeting AR-expressing prostate tumor cells fails in most prostate cancer patients who consequently develop castration-resistant prostate cancer (CRPC), an incurable disease2,3. This evidence concerns the gene AR and prostate cancer.